Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01177410 · ClinicalTrials.gov registry record · Phase 2
Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea
A Phase 2 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
NCT01177410 is a Phase 2 study that has completed, run by Bausch Health Americas. The registered enrollment target is 148 participants.
The verdict
NCT01177410, a Phase 2 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the daily dose of mesalamine granules that will provide adequate relief from symptoms of IBS with diarrhea.
Interventions
- DRUG Placebo
- DRUG Mesalamine Granules 750 mg
- DRUG Mesalamine Granules 1500 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01177410
The ClinicalTrials.gov registry entry for NCT01177410 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01177410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01177410 about?
NCT01177410 is a clinical study titled "Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea". The purpose of this study is to determine the daily dose of mesalamine granules that will provide adequate relief from symptoms of IBS with diarrhea.
What is the current status of trial NCT01177410?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2010-07. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01177410?
The interventions under investigation include: Placebo (DRUG), Mesalamine Granules 750 mg (DRUG), Mesalamine Granules 1500 mg (DRUG).
Who is sponsoring clinical trial NCT01177410?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.